All In Biotech

Drug Trial Radar · NCT00077636

ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.

A Randomized, Open-label Study of the Effect of PEGASYS and Ribavirin Combination Therapy on Sustained Virologic Response in Interferon-naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection

Last checked: Nov 20, 2026Latest source record: Feb 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,469 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,469

Actual

Start

Dec 2003

Primary completion

Mar 2006

Study completion Mar 2006

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Feb 13, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy and safety of different durations of treatment with PEGASYS combined with ribavirin in patients with CHC genotype 2 or 3 infection who have never previously received interferon (IFN) therapy. The anticipated time on study treatment is 3-12 months and the target sample size is 500+ individuals.

Conditions

  • Hepatitis C, Chronic

Interventions

  • CopegusDrug

    400mg po bid for 16 weeks

  • CopegusDrug

    400mg po bid for 24 weeks

  • peginterferon alfa-2a [Pegasys]Drug

    180 micrograms sc weekly for 16 weeks

  • peginterferon alfa-2a [Pegasys]Drug

    180 micrograms sc weekly for 24 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Sustained Virological Response (SVR)Time frame: Week 40 (for 16-week treatment group); Week 48 (for 24-week treatment group)

Locations

132 sites in 9 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Mobile, Alabama

  • Site not named

    Anchorage, Alaska

  • Site not named

    Phoenix, Arizona

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    La Jolla, California

  • Site not named

    Long Beach, California

  • Site not named

    Los Angeles, California

  • Site not named

    Palo Alto, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    San Francisco, California

  • Site not named

    San Luis Obispo, California

  • Site not named

    Littleton, Colorado

  • Site not named

    Farmington, Connecticut

  • Site not named

    Bradenton, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Jacksonville, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Wellington, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Austell, Georgia

  • Site not named

    Honolulu, Hawaii

  • Site not named

    Boise, Idaho

  • Site not named

    Moline, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Iowa City, Iowa

  • Site not named

    Iowa City, Iowa

  • Site not named

    Baton Rouge, Louisiana

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Baltimore, Maryland

Showing 40 of 132 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.